Inclusion Criteria:

- CD19+ ALL relapsed after allogeneic SCT.

- No active GVHD and off immunosuppression for greater than or equal to 4 weeks.

- Age greater than or equal to 18 years.

- Creatinine less than or equal to2.5 mg/dl.

- ALT/AST less than or equal to3x normal

- Bilirubin less than or equal to2.0 mg/dl

- Donor is available and is able to undergo apheresis. A separate donor consent process
and form is described below.

- Voluntary informed consent is given.

Exclusion Criteria:

- Pregnant or lactating women. The safety of this therapy on unborn children is not
known. Female study participants of reproductive potential must have a negative serum
or urine pregnancy test performed within 48 hours before infusion.

- Uncontrolled active infection.

- Active hepatitis B or hepatitis C infection.

- Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not
exclusionary.

- Previously treatment with any gene therapy products.

- Feasibility assessment during screening demonstrates less than 30% transduction of
target lymphocytes, or insufficient expansion ( less than 5-fold) in response to
CD3/CD28 costimulation..

- Any uncontrolled active medical disorder that would preclude participation as
outlined.

- HIV infection.

- Patients with active CNS involvement with leukemia. Patients with prior CNS disease
that has been effectively treated will be eligible providing treatment was greater
than or equal to 4 weeks before enrollment

- Patients with active GVHD or requiring immune suppression.